Home › NDC Lookup › Ingredients › Baclofen › 16571-0169-01
Baclofen 5 mg Tablet, 100-count — NDC 16571-0169-01 package photo
Label image from the product's FDA listing (DailyMed) — may show a different pack size or an older label revision.

Baclofen 5 mg Tablet, 100-count — NDC 16571-169-01 (Billing 16571-0169-01)

by Rising Pharma Holdings, Inc. · 100 TABLET in 1 BOTTLE

This is a package of 100 tablets of Baclofen 5 mg Tablet from Rising Pharma Holdings, Inc., marketed since Mar 2024 and currently FDA-listed; retail pharmacies pay about $0.0680 per tablet (NADAC). It is this product's only package size.

NDC 16571-0169-01
🏷️ FDA NDC (as labeled) 16571-169-01 billing pads the product segment with a zero
Rx only Generic On market Non-controlled ⇄ Compare with another NDC
🗂️ FDA directory synced Oct 1, 2026 · this listing last changed Jul 24, 2026 · sources: openFDA · FDA label (DailyMed) · FDA Orange & Purple Book · First Databank · CMS NADAC, ASP, Medicare & Medicaid · RxNorm
📋 All sources & update times →

This page is curated, coded, and maintained by

Compiled from public FDA, CMS, DailyMed, NADAC, and related drug data sources. Editorial policy

⚠️
Other active recalls for Baclofen (different manufacturers) — 1 · tap to view
These affect other manufacturers’ products for the same ingredient — not necessarily the exact NDC on this page.
Class II · Nov 26, 2025 — Presence of Foreign Tablets/Capsules (Golden State Medical Supply Inc.) · FDA recall D-0235-2026
Each entry is an official FDA enforcement report — look up any recall number in the FDA recall database ↗

Identity & classification

Regulatory identifiers FDA, NLM and CMS codes for this package

FDA NDC (as labeled) 16571-169-01
Product NDC 16571-169
11-digit billing NDC 16571016901
NCPDP billing unit EA — each (per item)
RxCUI 197391, 197392, 430902
UNII H789N3FKE8
Application # ANDA214374
SPL Set ID 6eb46715-d72b-473f-b984-90024033d4a0
Established class (EPC) gamma-Aminobutyric Acid-ergic Agonist
Mechanism of action GABA A Agonists; GABA B Agonists
DEA schedule Non-controlled
Marketing category ANDA
Marketing status On market
FDA listing status Listed (active directory)
Marketing start 2024-03-01
Route ORAL
Dosage form TABLET
Substance BACLOFEN
TE code (Orange Book) AB · RLD · RS

Drug-database identifiers Medi-Span GPI and First Databank GCN / HICL / AHFS classification

GPI-14 75100010000303
GCN Seq No 027229
GCN 18012
HICL code 001949
Ingredient (HICL) Baclofen
HIC1 code H
Therapeutic class — broad (HIC1) Nervous System (Except Autonomic)
HIC2 code H6
Therapeutic class — intermediate (HIC2) Drugs Acting Principally On The Midbrain
HIC3 code H6H
Therapeutic class — specific (HIC3) Skeletal Muscle Relaxants
AHFS code 12:20.12.00
AHFS class Gaba-Derivative Skeletal Muscle Relaxant
FDB label name BACLOFEN 5 MG TABLET
FDB brand name Baclofen
Legend status F — Federal legend — prescription drug or device
Quick answers
  • GSN (GCN sequence number): 027229
  • GCN: 18012
  • GPI-14 (Medi-Span): 75100010000303
  • HICL (First Databank): 001949
  • AHFS class code: 12:20.12.00
  • RxCUI (RxNorm): 197391
Why two NDCs? The FDA registers this code as 16571-169-01 — a 5-3-2 layout, and that's what's printed on the package and shown on DailyMed. For insurance claims, every NDC is standardized to a uniform 11-digit 5-4-2 format by adding a zero to the product segment → 16571-0169-01. Same drug, same package — only the format differs.
Where does this data come from?
Identifiers from the FDA openFDA NDC Directory and Structured Product Labeling; RxCUI from RxNorm (NLM); GPI from Medi-Span; GCN / HIC / AHFS / legend from First Databank.

RxNorm drug class

This medicine belongs to the gamma-Aminobutyric Acid-ergic Agonist class.

Pharmacologic class gamma-Aminobutyric Acid-ergic Agonist
Drug family (ATC) Other centrally acting agents
How it works GABA B Agonists, GABA A Agonists
Where does this data come from?
Therapeutic classes from RxNorm RxClass (U.S. National Library of Medicine) — Established Pharmacologic Class (FDA), ATC drug family (WHO) and mechanism of action, matched by this product’s RxCUI.

Clinical

Label name BACLOFEN 5 MG TABLET Ingredient Baclofen
📗 Our plain-language guide HelloPharmacist
  • It eases spasticity, meaning stiff, tight muscles and spasms. Oral forms are used mainly for spasticity from multiple sclerosis and may help with spinal cord injuries. Intrathecal...
  • Oral baclofen is usually started low and split into several doses a day, then increased slowly. Follow your prescriber and label. With liquids, double-check both the mg and mL on y...
  • Don't stop suddenly. Your dose should be lowered slowly. With an intrathecal pump, missing a refill can cause dangerous withdrawal, so keep every appointment.
  • Sleepiness, dizziness, nausea, headache, low blood pressure and muscle weakness are common. Avoid driving until you know how it affects you, and avoid alcohol.
📖 Read our full Baclofen guide →
Where does this data come from?
Plain-language summary from MedlinePlus (U.S. National Library of Medicine); supplement & herbal interactions and nutrient depletion data from the Natural Medicines database; our full guide is HelloPharmacist editorial content.

Pricing

A drug doesn't have one price. Each row is a different public payment system, and none is what you'd pay at the counter — that depends on your insurance. The ⓘ on each row explains what it measures.

Price systemPer eaPer package
Retail pharmacies payNADAC · weekly $0.068 $6.80 / 100 tablets
Medicaid paysCMS SDUD · 12 mo $0.2195 $21.95 / 100 tablets
Medicare drug plans payPart D · Q2 2026 $0.1147 $11.47 / 100 tablets
NADAC price history (per ea) — tap or hover for the price & month
Dec 2025 Mar 2026 Jun 2026 Sep 2026 $0.098 $0.063
▼ Down 31% over the last 10 months.
Where does this data come from?
NADAC (National Average Drug Acquisition Cost) is the CMS weekly pharmacy-acquisition-cost survey — what pharmacies pay. ASP (Average Sales Price) is the CMS Medicare Part B drug-payment file, published quarterly. Medicaid pays is computed by us from CMS State Drug Utilization Data (total reimbursed ÷ units, trailing 12 months) — gross of rebates and inclusive of dispensing fees, so it reflects what Medicaid paid, not an acquisition cost. Medicare drug plans pay is the median negotiated point-of-sale unit cost across plans listing this NDC in the CMS quarterly Prescription Drug Plan pricing files, before rebates. The VA pays is the federal contract price (FSS, and the statutory Big 4 ceiling where listed) from the VA National Acquisition Center pharmaceutical price file. All are free public government data; each measures a different payer, so the figures are not directly comparable.

Packaging — all sizes for this product

Package NDCDescription Marketing startMarketing endStatus
16571-0169-01 You're viewing this Main listing 100 TABLET in 1 BOTTLE 2024-03-01 — Active

Therapeutic equivalents

ProductLabelerPackNADAC/unitTEStatusPrice vs. this
Baclofen 5 mg 00527-1333-01 Lannett 100 tablets $0.068 AB Availability likely —
Baclofen 5 mg 00904-7558-06 Major 50 tablets $0.068 AB Availability likely —
Baclofen 5 mgthis 16571-0169-01 Rising 100 tablets $0.068 AB Availability likely —
Baclofen 5 mg 29300-0474-01 Unichem 100 tablets $0.068 AB Availability likely —
Baclofen 5 mg 50268-0105-15 AvPAK 50 tablets $0.068 AB Availability likely —
Baclofen 5 mg 52817-0319-10 TruPharma 100 tablets $0.068 AB Availability likely —
Baclofen 5 mg 58657-0730-01 Method 100 tablets $0.068 AB Availability likely —
Baclofen 5 mg 58657-0930-01 Method 100 tablets $0.068 AB Availability likely —
Baclofen 5 mg 60687-0804-65 American 50 tablets $0.068 AB Availability likely —
Baclofen 5 mg 62135-0472-90 Chartwell 90 tablets $0.068 AB Availability likely —
Baclofen 5 mg 70710-1609-01 Zydus 100 tablets $0.068 AB Availability likely —
Baclofen 5 mg 70756-0085-11 Lifestar 100 tablets $0.068 AB Availability likely —
Baclofen 5 mg 71930-0066-12 Eywa 100 tablets $0.068 AB Availability likely —
Baclofen 5 mg 72888-0009-01 Advagen 100 tablets $0.068 AB Availability likely —
Baclofen 5 mg 00615-8518-05 NCS 15 tablets — AB FDA listed —
Baclofen 5 mg 42571-0427-01 Micro 100 tablets — AB Discontinued —
Baclofen 5 mg 51407-0972-01 Golden 100 tablets — AB FDA listed —
Baclofen 5 mg 55154-4349-00 Cardinal 10 tablets — AB FDA listed —
Baclofen 5 mg 70518-4656-00 REMEDYREPACK 14 tablets — AB FDA listed —
Baclofen 5 mg 70771-1586-01 Zydus 100 tablets — AB FDA listed —
Baclofen 5 mg 71335-3050-01 Bryant 30 tablets — AB FDA listed —
Baclofen 5 mg 71335-3051-01 Bryant 30 tablets — AB FDA listed —
Baclofen 5 mg 72162-2372-01 Bryant 100 tablets — AB FDA listed —
Baclofen 5 mg 72162-2448-01 Bryant 100 tablets — AB FDA listed —
Baclofen 5 mg 72789-0478-01 PD-Rx 100 tablets — AB FDA listed —
Baclofen 5 mg 72865-0296-01 XLCare 100 tablets — AB FDA listed —
Baclofen 5 mg 76420-0356-01 Asclemed 100 tablets — AB FDA listed —
Baclofen 5 mg 82804-0219-90 Proficient 90 tablets — AB FDA listed —
Baclofen 5 mg 84386-0035-93 Aurobindo 9000 tablets — AB FDA listed —
About this product: this is a generic version of the medicine. FDA equivalence ratings are shown when available, and other versions are listed above, least expensive first.
Where does this data come from?
Equivalents are other NDCs of the same ingredient, form and route from the openFDA NDC Directory, ranked least-expensive-first by NADAC. Therapeutic-equivalence (AB) ratings come from the FDA Orange Book; biologics use the FDA Purple Book for biosimilar & interchangeable status.

Availability & generic status

🏛️
2024
On the market since
Mar 2024
📍
2026
Currently FDA-listed
2 years listed
🔓
·
Generic on the market
this product is a generic
✅This is a generic drug

This product is an FDA-approved generic. Other versions of the same drug are listed under Therapeutic equivalents, least expensive first.

Where does this data come from?
Patents and exclusivity from the FDA Orange Book (small-molecule drugs), refreshed from public FDA data. Generic launch timing is an estimate, not a guarantee.

What it looks like

Color white
ShapeRound
ImprintKP02;20
Size11 mm
ScoringScored — splits in 2
One label can cover several strengths, so colors may be combined — always confirm a loose pill against the dispensed prescription label or a pharmacist.
Where does this data come from?
Physical description (imprint, shape, color, scoring, coating) from this product’s FDA Structured Product Labeling (SPL), mirrored from DailyMed / openFDA.

Inactive Ingredients / Excipients

Inactive ingredients, also called excipients, are components of the drug product other than the active ingredient. They may include fillers, dyes, coatings, preservatives, flavors, or other formulation ingredients.

Loading inactive ingredients from the official FDA label in the background. No external source is being called by this page request.
Where does this data come from?
Source: official FDA Structured Product Labeling (SPL) via DailyMed and the openFDA label index. Structured IACT rows and label-wide narrative are kept separate; availability and product-level specificity depend on the submitted label.

Inactive ingredient FAQ

Are inactive ingredients the same for every manufacturer?
No. Inactive ingredients can differ by manufacturer, dosage form, strength, and package / product version.
Why might an inactive ingredient be missing?
Some SPLs do not provide a complete structured inactive-ingredient list, and older or unusual labels may only include the information in narrative text.
Can inactive ingredients matter?
Yes. They can matter for allergies, intolerances, dyes, gluten / lactose concerns, preservatives, and formulation differences — but confirm with a pharmacist or the manufacturer when it’s clinically important.

Manufacturer & labeler

LabelerRising Pharma Holdings, Inc.
Application holderRISING PHARMA HOLDINGS INC
FDA applicationANDA214374 (ANDA)
Labeler code16571
First marketedMar 2024
Product typeHuman Prescription Drug
Portfolio525 products on file
The labeler markets the product; the application holder owns the FDA approval. They’re often the same company but can differ (e.g. a repackager or an authorized generic). A mailing address / phone appears here when the manufacturer includes it in the product’s FDA label (not all do).
Where does this data come from?
Labeler, application holder and registered establishment from the FDA openFDA NDC Directory and Drugs@FDA; address/contact from the product’s FDA label.

Full prescribing information FDA SPL

The complete FDA label for this product — the official prescribing information, verbatim, section by section. Jump with a chip, search within the label, or expand everything.
🎯 Indications and Usage ⏱️ Dosage and Administration ⛔ Contraindications ⚠️ Warnings 🤒 Adverse Reactions 🆘 Overdosage 🧬 Clinical Pharmacology 📦 How Supplied / Storage and Handling 📋 Description ⚠️ Precautions 📄 Package Label / Principal Display Panel
🎯 Indications and Usage 109 words ▾

INDICATIONS AND USAGE Baclofen tablets are useful for the alleviation of signs and symptoms of spasticity resulting from multiple sclerosis, particularly for the relief of flexor spasms and concomitant pain, clonus, and muscular rigidity. Patients should have reversible spasticity so that baclofen treatment will aid in restoring residual function. Baclofen tablets, USP may also be of some value in patients with spinal cord injuries and other spinal cord diseases.

Baclofen tablets are not indicated in the treatment of skeletal muscle spasm resulting from rheumatic disorders. The efficacy of baclofen in stroke, cerebral palsy, and Parkinson’s disease has not been established and, therefore, it is not recommended for these conditions.

⏱️ Dosage and Administration 121 words ▾

DOSAGE AND ADMINISTRATION The determination of optimal dosage requires individual titration. Start therapy at a low dosage and increase gradually until optimum effect is achieved (usually between 40 to 80 mg daily). The following dosage titration schedule is suggested: 5 mg t.i.d. for 3 days 10 mg t.i.d. for 3 days 15 mg t.i.d. for 3 days 20 mg t.i.d. for 3 days Thereafter additional increases may be necessary but the total daily dose should not exceed a maximum of 80 mg daily (20 mg q.i.d.).

The lowest dose compatible with an optimal response is recommended. If benefits are not evident after a reasonable trial period, patients should be slowly withdrawn from the drug (see WARNINGS , Abrupt Drug Withdrawal ).

⛔ Contraindications 4 words ▾

CONTRAINDICATIONS Hypersensitivity to baclofen.

⚠️ Warnings ~1 min read ▾

WARNINGS a. Neonatal Withdrawal Symptoms: Withdrawal symptoms have been reported starting hours to days after delivery in neonates whose mothers were treated with oral baclofen throughout pregnancy. The symptoms of withdrawal in these infants have included increased muscle tone, tremor, jitteriness, and seizure.

If the potential benefit justifies the potential risk to the fetus and oral baclofen is continued during pregnancy, gradually reduce the dose and discontinue baclofen before delivery. If slow withdrawal is not feasible, advise the parents or caregivers of the potential for neonatal withdrawal. b. Abrupt Drug Withdrawal: Hallucinations and seizures have occurred on abrupt withdrawal of baclofen.

Therefore, except for serious adverse reactions, the dose should be reduced slowly when the drug is discontinued. c. Impaired Renal Function: Because baclofen is primarily excreted unchanged through the kidneys, it should be given with caution, and it may be necessary to reduce the dosage. d. Stroke : Baclofen has not significantly benefited patients with stroke.

These patients have also shown poor tolerability to the drug. e. Pregnancy : Baclofen has been shown to increase the incidence of omphaloceles (ventral hernias) in fetuses of rats given approximately 13 times the maximum dose recommended for human use, at a dose which caused significant reductions in food intake and weight gain in dams. This abnormality was not seen in mice or rabbits.

There was also an increased incidence of incomplete sternebral ossification in fetuses of rats given approximately 13 times the maximum recommended human dose, and an increased incidence of unossified phalangeal nuclei of forelimbs and hindlimbs in fetuses of rabbits given approximately 7 times the maximum recommended human dose. In mice, not teratogenic effects were observed, although reductions in mean fetal weight with consequent delays in skeletal ossification were present when dams were given 17 and 34 times the human daily dose.

There are no studies in pregnant women. Baclofen should be used during pregnancy only if the benefit clearly justifies the potential risk to the fetus.

🤒 Adverse Reactions ~1 min read ▾

ADVERSE REACTIONS The most common is transient drowsiness (10 to 63%). In one controlled study of 175 patients, transient drowsiness was observed in 63% of those receiving baclofen compared to 36% of those in the placebo group. Other common adverse reactions are dizziness (5 to 15%), weakness (5 to 15%) and fatigue (2 to 4%).

Others reported: Neuro psychiatric : Confusion (1 to 11%), headache (4 to 8%), insomnia (2 to 7%); and, rarely, euphoria, excitement, depression, hallucinations, paresthesia, muscle pain, tinnitus, slurred speech, coordination disorder, tremor, rigidity, dystonia, ataxia, blurred vision, nystagmus, strabismus, miosis, mydriasis, diplopia, dysarthria, epileptic seizure. Cardiovascular : Hypotension (0 to 9%). Rare instances of dyspnea, palpitation, chest pain, syncope.

Gastrointestinal: Nausea (4 to 12%), constipation (2 to 6%); and rarely, dry mouth, anorexia, taste disorder, abdominal pain, vomiting, diarrhea, and positive test for occult blood in stool. Genitourinary: Urinary frequency (2 to 6%); and rarely, enuresis, urinary retention, dysuria, impotence, inability to ejaculate, nocturia, hematuria. Other: Instances of rash, pruritus, ankle edema, excessive perspiration, weight gain, nasal congestion.

Some of the CNS and genitourinary symptoms may be related to the underlying disease rather than to drug therapy. The following laboratory tests have been found to be abnormal in a few patients receiving baclofen: increased SGOT, elevated alkaline phosphatase, and elevation of blood sugar. To report SUSPECTED ADVERSE REACTIONS, contact Rising Pharma Holdings, Inc. at 1-844-874-7464 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

🆘 Overdosage 59 words ▾

OVERDOSAGE Signs and Symptoms : Vomiting, muscular hypotonia, drowsiness, accommodation disorders, coma, respiratory depression and seizures. Treatment: In the alert patient, empty the stomach promptly by induced emesis followed by lavage. In the obtunded patient, secure the airway with a cuffed endotracheal tube before beginning lavage (do not induce emesis). Maintain adequate respiratory exchange, do not use respiratory stimulants.

🧬 Clinical Pharmacology 147 words ▾

CLINICAL PHARMACOLOGY The precise mechanism of action of baclofen is not fully known. Baclofen is capable of inhibiting both monosynaptic and polysynaptic reflexes at the spinal level, possibly by hyperpolarization of afferent terminals, although actions at supraspinal sites may also occur and contribute to its clinical effect. Although baclofen is an analog of the putative inhibitory neurotransmitter gamma-aminobutyric acid (GABA), there is no conclusive evidence that actions on GABA systems are involved in the production of its clinical effects.

In studies with animals baclofen has been shown to have general CNS depressant properties as indicated by the production of sedation with tolerance, somnolence, ataxia, and respiratory and cardiovascular depression. Baclofen is rapidly and extensively absorbed and eliminated. Absorption may be dose-dependent, being reduced with increasing doses.

Baclofen is excreted primarily by the kidney in unchanged form and there is relatively large intersubject variation in absorption and/or elimination.

📦 How Supplied / Storage and Handling 213 words ▾

HOW SUPPLIED Baclofen Tablets, USP 5 mg are available as off white to White, round flat-faced, beveled edge debossed ‘KP02’ on one side and ‘5’ on other side, containing 5 mg baclofen USP packaged in bottles of 100 tablets. NDC 16571-169-01 100s count Baclofen Tablets, USP 10 mg are available as off white to White, round flat-faced, beveled edge debossed ‘KP02’ on one side and ‘10’ with score on the other side, containing 10 mg baclofen USP packaged in bottles of 100, 500 and 1000 tablets. NDC 16571-171-01 100s count NDC 16571-171-50 500s count NDC 16571-171-10 1000s count Baclofen Tablets, USP 20 mg are available as off white to White, round flat-faced, beveled edge debossed ‘KP02’ on one side and ‘20’ with score on the other side, containing 20 mg baclofen USP packaged in bottles of 100, 500 and 1000 tablets.

NDC 16571-172-01 100s count NDC 16571-172-50 500s count NDC 16571-172-10 1000s count PHARMACIST: Dispense in a well-closed container as defined in the USP, with a child-resistant closure (as required). Store at 20°C to 25°C (68°F to 77°F) [See USP Controlled Room Temperature]. KEEP THIS AND ALL MEDICATIONS OUT OF THE REACH OF CHILDREN.

Manufactured for: Rising Pharma Holdings, Inc. East Brunswick, NJ 08816 Made in India Code No. DRUGS/TS/23/2007 Issued: 01/2024 PIR17210-00

📋 Description 96 words ▾

DESCRIPTION Baclofen, USP is a muscle relaxant and antispastic. Its chemical name is 4-amino-3-(4-chlorophenyl)-butanoic acid. The structural formula is: C 10 H 12 ClNO 2 M.W.

213.66 Baclofen, USP is a white to off-white odorless or practically odorless crystalline powder. It is slightly soluble in water, very slightly soluble in methanol and insoluble in chloroform. Each tablet, for oral administration, contains 5 mg, 10 mg or 20 mg baclofen, USP.

In addition, each tablet contains the following inactive ingredients: Microcrystalline Cellulose, Primecel, Starch 1500, Pre-gelatinized Maize Starch, Povidone K-30, Colloidal Silicone dioxide, and Magnesium Stearate. baclofen-struc

⚠️ Precautions ~1 min read ▾

PRECAUTIONS Because of the possibility of sedation, patients should be cautioned regarding the operation of automobiles or other dangerous machinery, and activities made hazardous by decreased alertness. Patients should also be cautioned that the central nervous system effects of baclofen may be additive to those of alcohol and other CNS depressants. Baclofen should be used with caution where spasticity is utilized to sustain upright posture and balance in locomotion or whenever spasticity is utilized to obtain increased function.

In patients with epilepsy, the clinical state and electroencephalogram should be monitored at regular intervals, since deterioration in seizure control and EEG have been reported occasionally in patients taking baclofen. It is not known whether this drug is excreted in human milk. As a general rule, nursing should not be undertaken while a patient is on a drug since many drugs are excreted in human milk.

A dose-related increase in incidence of ovarian cysts and a less marked increase in enlarged and/or hemorrhagic adrenal glands was observed in female rats treated chronically with baclofen. Ovarian cysts have been found by palpation in about 4% of the multiple sclerosis patients that were treated with baclofen for up to one year. In most cases these cysts disappeared spontaneously while patients continued to receive the drug.

Ovarian cysts are estimated to occur spontaneously in approximately 1% to 5% of the normal female population. Pediatric Use Safety and effectiveness in pediatric patients below the age of 12 years have not been established.

📄 Package Label / Principal Display Panel 52 words ▾

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL NDC 16571-169-01 Baclofen Tablets, USP 5 mg Rx Only 100 Tablets Rising Pharma Holdings, Inc. NDC 16571-171-01 Baclofen Tablets, USP 10 mg Rx Only 100 Tablets Rising Pharma Holdings, Inc. NDC 16571-172-01 Baclofen Tablets, USP 20 mg Rx Only 100 Tablets Rising Pharma Holdings, Inc. baclofen-5mg-100ct baclofen-10mg-100ct baclofen-20mg-100ct

Source: FDA Structured Product Labeling, mirrored from DailyMed / openFDA. Prefer the government’s original formatting? View this label on DailyMed ↗

Medicaid utilization & spend

📍 This exact package only: Medicaid data is reported per full 11-digit NDC — labeler, product and pack size — so every number here is for this package alone, not the drug overall. Other pack sizes report separately.
💊 Pharmacy benefit only: These are Medicaid outpatient pharmacy claims, billed by NDC. They exclude the medical benefit — clinic- or hospital-administered drugs billed under HCPCS J-codes — so drugs used mostly that way (e.g. Avastin, Lucentis, Keytruda) can look low or missing here. That’s expected, not an error.
📅 Q1 2025 – Q4 2025 · 4 quarters of data
ⓘ The newest quarter is usually incomplete when first published; states restate recent quarters in later CMS releases, so the latest figures typically revise upward. State coverage-policy changes can also shift quarter-to-quarter totals.
Prescriptions last 4 qtrs
27.4K
Units reimbursed last 4 qtrs
2M
Gross reimbursed last 4 qtrs
$436.6K
Avg / prescription
$15.94
Avg / unit
$0.2195
Latest quarter Q4 2025
6.8KRx
Medicaid pays / ea
$0.2195
gross reimbursed
vs
NADAC / ea
$0.0680
acquisition cost
=
Spread
+$0.1515
+223% vs cost
What Medicaid paid per ea (before rebates; includes the pharmacy’s dispensing fee) compared with NADAC — the average price pharmacies pay to buy the drug. A positive spread means Medicaid reimbursed more than the purchase price, before manufacturer rebates.
Fee-for-service vs managed care ⓘ
42% FFS 58% MCO
Fee-for-service · 11,468 Rx Managed care · 15,918 Rx
State Medicaid map
Alaska: no data reported AK Maine: no data reported ME Washington: no data reported WA Idaho: no data reported ID Montana: no data reported MT North Dakota: no data reported ND Minnesota: 14,369 units · 250 per 100k residents MN Wisconsin: 22,317 units · 378 per 100k residents WI Michigan: 133,512 units · 1,330 per 100k residents MI New York: 347,759 units · 1,777 per 100k residents NY Vermont: 12,751 units · 1,971 per 100k residents VT New Hampshire: 1,453 units · 104 per 100k residents NH Oregon: no data reported OR Nevada: 3,659 units · 115 per 100k residents NV Wyoming: no data reported WY South Dakota: no data reported SD Iowa: 6,644 units · 207 per 100k residents IA Illinois: 67,977 units · 542 per 100k residents IL Indiana: 189,000 units · 2,754 per 100k residents IN Ohio: 167,852 units · 1,424 per 100k residents OH Pennsylvania: 337,308 units · 2,602 per 100k residents PA New Jersey: 41,980 units · 452 per 100k residents NJ Massachusetts: 24,466 units · 349 per 100k residents MA California: 43,618 units · 112 per 100k residents CA Utah: no data reported UT Colorado: 20,904 units · 356 per 100k residents CO Nebraska: 4,910 units · 248 per 100k residents NE Missouri: 79,174 units · 1,278 per 100k residents MO Kentucky: 31,116 units · 687 per 100k residents KY West Virginia: 23,193 units · 1,310 per 100k residents WV Virginia: 41,939 units · 481 per 100k residents VA Maryland: 49,914 units · 808 per 100k residents MD Connecticut: 24,113 units · 667 per 100k residents CT Rhode Island: no data reported RI Arizona: 3,216 units · 43.3 per 100k residents AZ New Mexico: no data reported NM Kansas: 12,599 units · 429 per 100k residents KS Arkansas: 9,144 units · 298 per 100k residents AR Tennessee: 6,507 units · 91.3 per 100k residents TN North Carolina: 13,906 units · 128 per 100k residents NC South Carolina: 1,959 units · 36.5 per 100k residents SC Delaware: 7,392 units · 717 per 100k residents DE Oklahoma: no data reported OK Louisiana: 49,142 units · 1,074 per 100k residents LA Mississippi: 18,401 units · 626 per 100k residents MS Alabama: 8,056 units · 158 per 100k residents AL Georgia: no data reported GA D.C.: 2,014 units · 297 per 100k residents DC Hawaii: no data reported HI Texas: 75,801 units · 249 per 100k residents TX Florida: 91,373 units · 404 per 100k residents FL
Units reimbursed · per 100k residents
36.52,754
gray = no data reported ⓘ
Colors are per 100,000 residents, so big states don’t automatically dominate. Tap or hover a state for its actual totals.
Tap or hover a state
…for its Medicaid breakdown
🏆 Top states by units · per 100k residents
1 Indiana 2,754 /100k
2 Pennsylvania 2,602 /100k
3 Vermont 1,971 /100k
4 New York 1,777 /100k
5 Ohio 1,424 /100k
6 Michigan 1,330 /100k
7 West Virginia 1,310 /100k
8 Missouri 1,278 /100k
National units — by quarter
💵 About the dollar figures: “reimbursed” is what Medicaid paid pharmacies before confidential manufacturer rebates, so the program’s real net cost is lower than these numbers. Fee-for-service and managed-care claims are combined unless split above. Source: CMS State Drug Utilization Data; per-100k rates use 2023 Census population estimates.

Medicare Part D spend CMS · PART D · 2026 (Q1)

Medicare Part D (outpatient prescription) spending for Baclofen — the program that covers self-administered drugs. 23 manufacturers.
⚠️ Drug-level data: CMS publishes Part D spending by drug, not by NDC — these figures combine every manufacturer, strength and package size sold under the name Baclofen. That’s a different level of aggregation than the Medicaid card above, which is specific to this exact 11-digit NDC (pack size included), so the two aren’t directly comparable.
Period
Total Part D spend
$22.67M
Claims incl. refills
1.3M
Beneficiaries
744.4K
Spend / beneficiary
$30.45
Spend / claim
$17.31
Trend by period
💵 About the dollar figures: spending is what Part D plans paid before confidential manufacturer rebates, so the program’s real net cost is lower. A blank patient count means fewer than 11 people — CMS hides counts that small to protect privacy. Source: CMS Medicare Quarterly Part D Spending by Drug (data.cms.gov), updated quarterly.
← 16571-0168-01 · Rising 16571-0171-01 · Rising →
For educational and professional reference only — not medical advice. Pricing reflects published NADAC and CMS ASP (free public data) and may differ from your acquisition cost; always verify before billing or dispensing.